Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Insulin for Post-operative Delirium
NCT04635774Phase 2Withdrawn
- Sponsor
- University of Kansas Medical Center
- Start
- Feb 2021
- Primary completion
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Generex Oral-lyn in postoperative delirium (POD), sponsored by University of Kansas Medical Center. Planned start Feb 2021; status: withdrawn.
02
Drugs
Generex Oral-lyn
03
Conditions
postoperative delirium (POD)
Beyond the preview
Go deeper on NCT04635774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04635774.